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Abstract
The recently recognized renal cell carcinomas (RCCs) associated with Xp11.2 translocations (TFE3
transcription factor gene fusions) are rare tumors predominantly reported in children. They
comprise at least one-third of pediatric RCCs and only few adult cases have been reported. Here,
we present a case of Xp11.2 translocation RCC in 26-year-old pregnant female. Her routine
antenatal ultrasonography accidentally found a complex cystic right renal mass. Further radiologic
studies revealed unilocular cyst with multiple mural nodules at inferior pole of right kidney, which
was suspicious for RCC. She underwent right radical nephrectomy at 15 weeks gestation.
Macroscopically, the cystic tumor was well encapsulated with multiple friable mural nodules on its
inner surface. Microscopically, the tumor consisted of clear and eosinophilic/oncocytic voluminous
cells arranged in papillary, trabecular, and nested/alveolar patterns. Occasional hyaline nodules and
numerous psammoma bodies were present.
Immunohistochemically, the tumor showed strong nuclear positivity for TFE3. Epithelial membrane
antigen, CD10, and E-cadherin were strongly positive. Cytokeratin AE1/AE3, cytokeratin CAM-5.2,
calveolin, and parvalbumin were moderately positive. Cytokeratin 7, renal cell carcinoma antigen,
and colloidal iron were focally weakly positive. BerEP4 and carbonic anhydrase IX were negative.
Cytogenetically, the tumor harbored a novel variant translocation involving chromosomes X and
19, t(X;19)(p11.2;q13.1). Interphase FISH analysis performed on cultured and uncultured tumor
cells using a dual-color break-apart DNA probe within the BCL3 gene on 19q13.3 was negative for
the BCL3 gene rearrangement. She received no adjuvant therapy, delivered a normal term baby five
months later, and is alive without evidence of disease 27 months after diagnosis and surgery. Unlike
most recently reported Xp11.2 translocation RCCs in adult patients with aggressive clinical course,
this adult case occurring during pregnancy with a novel translocation involving chromosome 19
followed an indolent clinical course.
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Background
Xp11.2/TFE3 translocation renal cell carcinomas (RCCs),
a recently classified distinct subtype, are rare tumors that
usually affect children and adolescents [1-8], with only
few reported adult cases to date [9-24]. It is estimated that
approximately one-third of pediatric RCCs are Xp11.2
translocation RCCs [2-5], whereas conventional clear cell
RCCs make up about 15% of pediatric RCCs [25,26]. In
contrast, conventional clear cell RCCs make up 70% of
RCCs in adults and 53% in young adults [26], but the inci-
dence of Xp11.2 translocation RCCs in adults and young
adults is much smaller (estimated to be perhaps 1%)
[1,5,7,17,19,27]. Xp11.2 translocation RCCs are defined
by at least six different translocations involving the
Xp11.2 chromosome, all of which result from gene
fusions involving the TFE3 transcription factor gene, and
their morphology and biological behavior are not widely
recognized as yet [1-24]. They typically have papillary
and/or nested architecture, and are composed of cells with
clear and/or eosinophilic voluminous cytoplasm [1-24].
Translocations involving TFE3 induce overexpression of
this protein, and hence nuclear immunolabelling for TFE3
is a sensitive and specific marker of neoplasms with TFE3
gene fusions [1-8]. Although only limited data are availa-
ble thus far, they are believed to be rather indolent even
when diagnosed at advanced stages [1-8], but there have
been increasing recent reports of an aggressive clinical
course in adult cases [9-24].
Case presentation
The patient was a 26-year-old pregnant woman (14 weeks
gestation) who was accidentally found to have a complex
cystic renal mass during routine antenatal ultrasonogra-
phy. Subsequent magnetic resonance imaging (MRI) scan
revealed a unilocular cystic mass with multiple mural
nodules on its inner surface at the inferior pole of the right
kidney, which was interpreted as radiologically suspicious
for a RCC (Figure 1). She had no previous history of
chemotherapy. All blood test were unremarkable. The
patient underwent right radical nephrectomy at 15 weeks
gestation. Surgery revealed the tumor to be confined
within the kidney. The postoperative period was unevent-
ful and the patient was discharged four days after surgery.
She received no adjuvant therapy, and is alive without evi-
dence of disease 27 months after diagnosis and radical
nephrectomy. She delivered a normal term baby five
months after diagnosis and radical nephrectomy, and
macroscopic and microscopic evaluation of the placenta
was unremarkable with no evidence of metastatic RCC.
Methods
Histologic examination
Tissues were fixed in 10% buffered formalin solution and
embedded in paraffin blocks. Four-micrometer-thick sec-
tions were obtained and stained with hematoxylin and
eosin for microscopic examination.
Immunohistochemical analysis
Additional sections were used to perform immunohisto-
chemical studies using an avidin-biotin peroxidase tech-
nique with hematoxylin counterstain. The antibodies
used in this study include the following: cytokeratin AE1-
AE3 (clone AE1-AE3/PCK26, Ventana Medical Systems
Inc, Tucson, Arizona, USA), cytokeratin CAM-5.2 (clone
CAM-5.2, Becton-Dickinson Biosciences, San Jose, Cali-
fornia, USA), cytokeratin 7 (clone OV-TL 12/30, Ventana
Medical Systems Inc, Tucson, Arizona, USA), epithelial
membrane antigen (EMA, Clone E29, Ventana Medical
Systems Inc, Tucson, Arizona, USA), renal cell carcinoma
antigen (RCC, clone PN-15, Ventana Medical Systems Inc,
Tucson, Arizona, USA), CD 10 (clone 56C6, Ventana
Medical Systems Inc, Tucson, Arizona, USA), E-cadherin
(clone ECH-6, Ventana Medical Systems Inc, Tucson, Ari-
zona, USA), calveolin-1 (clone E249, Epitomics Inc, Burl-
ingame, California, USA), parvalbumin (PARV-19, Sigma-
Aldrich Company, St Louis, Missouri, USA), TFE3 (clone
H-300, Santa Cruz Biotechnology Inc, Santa Cruz, Califor-
nia, USA), carbonic anhydrase IX (CA9, clone M75, Dako-
Cytomation, Carpinteria, California, USA), and BerEP4
(clone M0804, DakoCytomation, Carpinteria, California,
USA). Mowry's colloidal iron stain was also performed on
tissue sections.
MRI scan showing unilocular cystic right renal mass with mul- tiple mural nodule Figure 1
MRI scan showing unilocular cystic right renal mass 
with multiple mural nodule.Diagnostic Pathology 2009, 4:15 http://www.diagnosticpathology.org/content/4/1/15
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We analyzed the intensity and immunoreactivity of the
immunostained sections. The intensity was graded quali-
tatively as weak, moderate, or strong on the basis of the
brown color produced by the 3, 3'-diaminobenzidine
chromogen. Diffuse and intense brown staining of the
cytoplasmic or nuclear surfaces, as appropriate for each
stain, was interpreted as strong staining intensity. Moder-
ate intensity staining was characterized as non-diffuse but
intense staining pattern, whereas weak intensity had a dif-
fuse but non-intense staining pattern. Immunoreactivity
was quantitatively estimated by the percentage of positive
cells per representative section. Immunoreactivity was
graded as 1+, 2+, and 3+, corresponding to less than 25%,
between 25% and 50%, and greater than 50% of neoplas-
tic cells showing positive staining per representative sec-
tion, respectively.
Cytogenetic analysis
A fresh unfixed tumor sample was submitted in RPMI tis-
sue culture medium to the Pittsburgh Cytogenetics Labo-
ratory of the Department of Pathology of the University of
Pittsburgh Medical Center for cytogenetic analysis. The
tumor tissue was treated with collagenase to enzymati-
cally dissociate cells, which were then cultured for 22
days. Metaphase cells were harvested from monolayer cell
cultures and chromosomes were GTG-banded using
standard procedures.
Fluorescence In Situ Hybridization (FISH) analysis
Two separate Fluorescence in situ hybridization (FISH)
assays were performed using interphase cells derived from
interphase cells harvested from monolayer cell cultures
prepared as described above and a formalin-fixed paraf-
fin-embedded section. Formalin-fixed paraffin-embedded
sections were mounted and serially sectioned at 4-mm
intervals. Separate sections stained with H & E were used
to determine the area of the tissue to be targeted for anal-
ysis. The formalin-fixed paraffin-embedded slides were
de-paraffinized in xylene twice for 10 minutes, dehy-
drated twice with 100% ethanol, and then pretreated
using the DakoCytomation Paraffin Pretreatment Kit
(DakoCytomation, Carpinteria, California, USA). Slides
were digested for 18 minutes in protease solution (0.5
mg/ml) at 37°C.
For both assays, FISH was performed using the BCL3
(19q13.3) dual-color break-apart DNA probe (DakoCyto-
mation, Carpinteria, California, USA). The target slide
and probe were co-denatured at 95°C for 8 minutes and
incubated overnight at 37°C in a humidified chamber.
Post-hybridization washes were performed using 2×
standard saline citrate/0.3% Igepal (Sigma) at 72°C for 2
minutes. Slides were air-dried in the dark and counter-
stained with 4',6'-diamidino-2-phenylindole (DakoCyto-
mation, Carpinteria, California, USA). Analysis was
performed using a Nikon Optiphot-2 microscope (Nikon,
Inc.) and Quips Genetic Workstation equipped with a
Chroma Technology filter fitted with single- band excitors
for SpectrumOrange, fluorescein isothiocyanate, and
4',6'-diamidino-2-phenylindole (uv 360 nm; DakoCyto-
mation, Carpinteria, California, USA). Only individual
and well-delineated cells were scored. Overlapping cells
were excluded from the analysis. A total of 222 and 162
cells were analyzed from the assays derived from monol-
ayer cell culture and formalin-fixed paraffin-embedded
section, respectively.
Results
Macroscopic findings
The right nephrectomy specimen was bivalved from the
peripheral cortex towards the hilum to show a 5.5 × 4.5 ×
3.5-cm well encapsulated, unilocular cystic tumor at the
inferior pole of the kidney. Serial sections of the tumor
revealed multiple soft and friable tan-gray mural nodules
arising or attached to the inner surface of the cyst, with
these nodules measuring up to 2.0 cm in greatest dimen-
sion (Figure 2). The tumor was confined to the kidney and
was present immediately deep to renal capsule. There was
no gross evidence of extension of the tumor into the renal
artery, renal vein, or renal sinus. No other lesions were
present in the adjacent renal parenchyma.
Microscopic findings
The renal tumor showed carcinomatous proliferation of
malignant epithelial cells arranged in papillary (Figures
3A &3B), trabecular, and nested/alveolar (Figure 3C) pat-
terns. The tumor cells were large with discrete cell borders
and had either abundant granular eosinophilic cytoplasm
Gross photograph of tumor after fixation showing unilocular  cystic tumor with multiple friable mural nodules Figure 2
Gross photograph of tumor after fixation showing 
unilocular cystic tumor with multiple friable mural 
nodules.Diagnostic Pathology 2009, 4:15 http://www.diagnosticpathology.org/content/4/1/15
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(imparting an oncocytic appearance, Figures 3A &3C) or
abundant granular finely vacuolated cytoplasm (impart-
ing a clear cell appearance, Figures 3A &3B). The nuclei
were mildly enlarged with mild contour irregularities, and
had fine chromatin with occasional prominent nucleoli
(Fuhrman nuclear grade 2 out of 4). The stroma was vas-
cular with occasional hyaline nodules and numerous
psammoma bodies (Figure 3D). Mitotic figures were not
identified. Abundant areas of central hemorrhagic necro-
sis containing hemosiderin-laden macrophages were
present. There was no evidence of lymphovascular inva-
sion, and all surgical resection margins were free of tumor.
Immunohistochemical findings
The immunohistochemical results are summarized in
Table 1. The neoplastic cells were diffusely strongly
immunoreactive (3+, cytoplasmic staining) for epithelial
membrane antigen (EMA) [Figure 4A], CD10 (Figure 4B),
and E-cadherin (Figure 4C). Nuclear staining for TFE3
(Figure 4D) was diffusely strongly immunoreactive (3+),
indicating the presence of the corresponding Xp11.2
translocation. The neoplastic cells were focally moder-
ately immunoreactive (2+, cytoplasmic staining) for
cytokeratin AE1-AE3 (Figure 5A), cytokeratin CAM-5.2
(Figure 5B), calveolin, and parvalbumin. The neoplastic
cells were focally weakly immunoreactive (1+, cytoplas-
mic staining) cytokeratin 7 (Figure 5C), renal cell carci-
noma antigen (Figure 5D), and colloidal iron. The
neoplastic cells did not express BerEP4 or carbonic anhy-
drase IX.
Cytogenetic findings
Fifteen trypsin-Giemsa banded metaphase cells were ana-
lyzed from five and six day harvests of monolayer primary
cell cultures and from a 22 day harvest of subcultured
monolayer cell cultures derived from the renal mass. Two
cells had an apparently normal female chromosome com-
plement, most likely representing the stromal cells. One
cell had a hypodiploid karyotype, likely as a result of ran-
dom chromosomal loss. Nine cells had a 46, X,
t(X;19)(p11.2;q13.1) chromosome pattern (Figure 6).
Three additional cells, each with this same abnormality,
had less than 46 chromosomes, likely as a result of ran-
dom chromosomal loss. In addition to the above cells, a
few cells with tetraploidy and endoreduplication with this
translocation were observed. Therefore, this renal tumor
showed a mosaic abnormal female chromosome analysis
with an apparently normal cell line and an abnormal
clone with a translocation between the short arm of an X
chromosome and the long arm of chromosome 19. The
overall karyotype results can be described by the follow-
ing International System for Human Cytogenetic Nomen-
clature (ISCN 2005): 46, X, t(X;19)(p11.2;q13.1)[12]/46,
XX[3]. This classical cytogenetic profile is consistent with
a diagnosis of Xp11.2 translocation RCC with a novel
translocation involving chromosome 19.
Fluorescence In Situ Hybridization (FISH) findings
In order to determine if the BCL3 (19q13.3) gene located
on the chromosome 19 was involved in the novel translo-
cation observed by the classical cytogentic analysis above
[t(X;19)(p11.2;q13.1)], cultured and uncultured tumor
cells were evaluated by interphase FISH analysis using a
dual-color break-apart DNA probe within the BCL3 gene
on 19q13.3. The FISH analysis was negative for the BCL3
gene rearrangement in 222 (100%) of the 222 interphase
cells examined from the assays derived from monolayer
cell culture. Twenty-two (10%) of the 222 interphase cells
examined from the assays derived from monolayer cell
culture had 1–2 extra BCL3 signals. The significance of the
presence of 10% of cells with 1–2 extra BCL3 signals is
unclear. It may suggest the presence of a small clone with
triploidy or tetraploidy. Tetraploidy was observed in a few
cells by the classical cytogentic analysis above. Addition-
ally, the FISH analysis was negative for the BCL3 gene
rearrangement in 161 (99.4%) of the 162 interphase cells
examined from the assays derived from formalin-fixed
paraffin-embedded section. The finding of 1 (0.6%) of the
162 interphase cells examined from the assays derived
from formalin-fixed paraffin-embedded section with a
split signal for BCL3 is below the 1–3% range for false
positive signals for break-apart DNA probes.
Discussion
We describe a case of a 26-year-old pregnant woman with
a Xp11.2/TFE3 translocation RCC with a novel transloca-
Histologic features of Xp11 translocation RCC with novel  breakpoints, t(X;19)(p11.2;q13.1) Figure 3
Histologic features of Xp11 translocation RCC with 
novel breakpoints, t(X;19)(p11.2;q13.1). A, Papillary 
pattern with admixed voluminous clear and eosinophilic cells. 
B, Papillary pattern with voluminous clear cells. C, Nested/
alveolar pattern with voluminous eosinophilic/oncocytic cells. 
D, Occasional hyaline nodules and numerous psammoma 
bodies.Diagnostic Pathology 2009, 4:15 http://www.diagnosticpathology.org/content/4/1/15
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tion involving chromosome 19, and a favorable clinical
course. The tumor shows a combination of clear and eosi-
nophilic granular voluminous cells in a mixed papillary
and nested pattern with the presence of prominent psam-
momatous calcification. The diagnosis is confirmed
immunohistochemically by strong nuclear immunoreac-
tivity for TFE3, and cytogenetically by the presence of a
Xp11.2 translocation. Translocations involving TFE3
induce overexpression of this protein, and can be specifi-
cally identified by immunohistochemistry [7]. Nuclear
labeling for TFE3 is highly sensitive (97.5%) and specific
(99.6%) for neoplasms bearing TFE3  gene fusions [7].
Argani et al. [7] reported that immunostaining of TFE3 is
nuclear and should, in case of positivity, be obvious at
low-power magnification. A reliable interpretation
requires the absence of cytoplasmic labeling of tumor
cells and absence of nuclear labeling in adjacent normal
kidney. Diagnosis of Xp11.2 translocation RCCs, which
remains underestimated in the absence of cytogenetic
studies on fresh or frozen materials, is therefore now pos-
sible on archival paraffin blocks [7,17]. The histologic fea-
tures of papillary and nested architecture, voluminous
clear and eosinophilic cytoplasm, and numerous psam-
moma bodies of the case herein presented raised the pos-
sibility of RCC associated with a Xp11.2 translocation.
However, the histology in some areas of the tumor and
immunophenotype also suggested an oncocytic renal epi-
thelial neoplasm with admixed clear/chromophobe cells
and distal tubular differentiation (eosinophilic variant of
chromophobe RCC versus appearance of RCC in patients
with Birt-Hogg-Dube syndrome versus oncocytoma ver-
sus unclassified RCC). This emphasizes that Xp11.2 trans-
location RCCs can have a variety of gross and histologic
appearances and significant heterogeneity within the
tumor, and may have overlapping immunophenotype
with other tumors. Hence, emphasizing the importance of
performing cytogenetic analysis and including the TFE3
immunostain in panels for RCCs with unusual features,
and probably for all RCCs in young patients.
Xp11.2 translocation RCC results from gene fusions
between the TFE3 transcription factor gene located on
chromosome Xp11.2 and one of six different gene fusion
partners previously reported to date [1-24]. The molecular
Table 1: Immunohistochemical findings of case of Xp11.2 translocation renal cell carcinoma with a novel translocation involving 
chromosome 19
Antibody to Result (Positive, Negative) Intensity 
(Strong, Moderate, Weak)
Immunoreactivity 
(1+, 2+, 3+)
Staining Pattern 
(Nuclear, Cytoplasmic)
TFE3 Positive Strong 3+ Nuclear
Cytokeratin AE1-AE3 Positive Moderate 2+ Cytoplasmic
Cytokeratin CAM-5.2 Positive Moderate 2+ Cytoplasmic
Cytokeratin 7 Positive Weak 1+ Cytoplasmic
Epithelial membrane 
antigen
Positive Strong 3+ Cytoplasmic
Renal cell carcinoma 
antigen
Positive Weak 1+ Cytoplasmic
CD 10 Positive Strong 3+ Cytoplasmic
E-cadherin Positive Strong 3+ Cytoplasmic
Calveolin Positive Moderate 2+ Cytoplasmic
Parvalbumin Positive Moderate 2+ Cytoplasmic
Colloidal iron Positive Weak 1+ Cytoplasmic
BerEP4 Negative Not Applicable Not Applicable Not Applicable
Carbonic anhydrase IX Negative Not Applicable Not Applicable Not Applicable
1+, < 25% Positive Cells; 2+, 25–50% Positive Cells; 3+, > 50% Positive CellsDiagnostic Pathology 2009, 4:15 http://www.diagnosticpathology.org/content/4/1/15
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identity of five of these six gene fusion partners of TFE3
are known, whilst the identity of the sixth which is situ-
ated on chromosome 3 is not yet known [1-24]. The five
known gene fusion partners of TFE3 are renal cell carci-
noma papillary 1 (PRCC), alveolar soft part sarcoma locus
(ASPL), polypyrimidine tract-binding protein-associated
splicing factor (PSF), non-POU domain-containing
octamer-binding (NonO, p54nrb), and clathrin heavy-
chain (CLTC) genes, situated on chromosome loci 1q21,
17q25, 1p34, Xq12, and 17q23, respectively (Table 2) [1-
24]. The t(X;17)(p11.2;q25) or TFE3-ASPL translocation
RCC and alveolar soft part sarcoma (ASPS) contain the
identical TFE3-ASPL fusion transcript; however, the
t(X;17) translocation is consistently balanced (reciprocal)
in the Xp11.2 translocation RCC and unbalanced in the
ASPS [1]. The classical cytogenetic profile of the tumor
herein reported indicates the majority of the tumor cells
with a translocation involving chromosome region
Xp11.2/TFE3 and chromosome region 19q13.1, suggest-
ing that the tumor is a Xp11.2 translocation RCC with a
novel translocation involving chromosome 19 and a
unilocular cystic and mural multinodular gross appear-
ance. Although, a cystic gross appearance is uncommon
for Xp11.2 translocation RCCs, Suzigan et al. [16] recently
reported a Xp11.2 translocation RCC in a 17-year-old
female with multilocular cystic RCC-like features, who
was alive with no evidence of disease four months after
diagnosis. However, an RCC with translocation involving
Xp11.2 to chromosome 19 has not been previously
reported. Therefore, our study further expands the genetic
spectrum of Xp11.2 translocation RCCs, in that we report
a novel translocation, t(X;19)(p11.2;q13.1). Since this
novel gene fusion partner of TFE3 at the 19q13.1 locus in
the case herein presented is close to the BCL3 (19q13.3)
gene located on the chromosome 19, interphase FISH
analysis was performed on cultured and uncultured
tumor cells using a dual-color break-apart DNA probe
within the BCL3 gene on 19q13.3. The tumor cells were
negative for the BCL3 gene rearrangement, indicating that
Immunohistochemical findings of Xp11 translocation RCC  with novel breakpoints, t(X;19)(p11.2;q13.1) Figure 4
Immunohistochemical findings of Xp11 translocation 
RCC with novel breakpoints, t(X;19)(p11.2;q13.1). A, 
Strongly positive cytoplasmic staining for epithelial mem-
brane antigen. B, Strongly positive cytoplasmic staining for 
CD10. C, Strongly positive cytoplasmic staining for E-cad-
herin. D, Strong nuclear labeling for TFE3 protein.
Immunohistochemical findings of Xp11 translocation RCC  with novel breakpoints, t(X;19)(p11.2;q13.1) Figure 5
Immunohistochemical findings of Xp11 translocation 
RCC with novel breakpoints, t(X;19)(p11.2;q13.1). A, 
Moderate positive cytoplasmic staining for cytokeratin AE1-
AE3. B, Moderate positive cytoplasmic staining for cytokera-
tin CAM-5.2. C, Focal weak positive cytoplasmic staining for 
cytokeratin 7. D, Focal weak positive cytoplasmic staining for 
renal cell carcinoma antigen.
Complete karyotype of Xp11 translocation RCC with novel  breakpoints, t(X;19)(p11.2;q13.1) Figure 6
Complete karyotype of Xp11 translocation RCC with 
novel breakpoints, t(X;19)(p11.2;q13.1).Diagnostic Pathology 2009, 4:15 http://www.diagnosticpathology.org/content/4/1/15
Page 7 of 11
(page number not for citation purposes)
the BCL3 gene is not the novel gene fusion partner of TFE3
in the case herein presented. Hence at this time, the
molecular identity of the gene fusion partner of TFE3 at
the 19q13.1 locus in the case herein presented remains
unknown, since reverse transcriptase polymerase chain
reaction (RT-PCR) analysis had yet to be successful at
detecting and identifying the TFE3 fusion transcript. Inter-
estingly, the neoplasm herein presented demonstrated
some of the typical histological features observed in the
TFE3-ASPL translocation RCCs, which harbor a
t(X;17)(p11.2;q25) chromosome translocation, in that its
cells had voluminous clear and eosinophilic cytoplasm
and were associated with abundant psammoma bodies
[5,14,17]. The case herein presented highlights the point
that the morphology of Xp11.2 translocation RCCs har-
boring different gene fusions may overlap significantly. At
the same time, the entire histologic architecture and
grossly cystic morphology of the case herein presented are
not classical of Xp11.2 translocation RCCs; and this might
reflect the morphologic heterogeneity in translocation
tumors, the influence of the novel translocation gene part-
ner, both, or some other factor. Nonetheless, in many
cases, the morphology may provide a clue to the specific
gene fusion.
Macroscopically, Xp11.2 translocation RCCs may mimic
conventional clear cell RCCs as they are usually tan-yel-
low, necrotic, and hemorrhagic. The most consistent his-
tologic appearance of Xp11.2 translocation RCC is a
carcinoma with mixed papillary and nested/alveolar
architecture, composed of cells with clear and/or eosi-
nophilic granular voluminous cytoplasm, discrete bor-
ders, vesicular chromatin, prominent nucleoli, and
psammoma bodies [1-24]. However, the TFE3-PRCC var-
iant is generally composed of cells of intermediate size
and shows few psammoma bodies; this is in contrast to
the TFE3-ASPL variant which generally shows large volu-
minous cells and presence of numerous psammoma bod-
ies [1-24], features reminiscent of the case herein
presented. In the case herein presented, the histological
sections of the resected renal tumour showed numerous
psammoma bodies, a feature that is rarely observed in
conventional clear cell RCC but can be seen in papillary
RCC [5,14,17]. The absence or paucity of true papillary
groups with smooth-bordered contours, foamy macro-
phages, nuclear grooves, stromal inflammatory cells and a
necrotic background did not support the diagnosis of pap-
illary or conventional clear cell RCC [5,14,17]. Xp11.2
translocation RCC can occur in adults and may be aggres-
sive cancers [9-24], and hence require morphologic dis-
tinction from conventional clear cell and papillary RCCs.
Although they may be uncommon on a percentage basis,
given the much higher prevalence of RCCs in adults com-
pared with children, adult Xp11.2 translocation RCC may
well outnumber their pediatric counterparts. Accurate his-
topathologic diagnosis, supported by confirmatory TFE3
immunohistochemistry (IHC), should allow this subset
of adult RCCs to be delineated such that their clinico-
pathologic features can be analyzed further. On routine
hematoxylin and eosin sections, Xp11.2 translocation
RCC may overlap significantly with conventional clear
cell and papillary RCCs in adults. The formation of papil-
lae is, at most, rare in clear cell RCC, although pseudopap-
illary areas arising from degeneration of acinar structures
may be difficult to distinguish from true papillae. Further-
more, clear cell RCC seldom, if ever, forms psammoma
Table 2: Reported cytogenetic translocations involving Xp11.2/transcription factor E3 (TFE3)
Chromosome Translocation Gene Fusion Neoplasm Source, Year
der(17)t(X;17)(p11.2;q25) ASPL-TFE3 ASPS Argani et al, 2001 [1];
Argani et al, 2007 [17]
t(X;17)(p11.2;q25) ASPL-TFE3 RCC Argani et al, 2001 [1];
Argani et al, 2007 [17]
t(X;1)(p11.2;q21) PRCC-TFE3 RCC Argani et al, 2007 [17]
t(X;1)(p11.2;p34) PSF-TFE3 RCC Argani et al, 2007 [17]
inv(X)(p11.2;q12) NONO-TFE3 RCC Argani et al, 2007 [17]
t(X;17)(p11.2;q23) CLTC-TFE3 RCC Argani et al, 2003 [8];
Argani et al, 2007 [17]
t(X;3)(p11.2;q23) Unknown RCC Argani et al, 2007 [17]
ASPL, alveolar soft part sarcoma locus; ASPS, alveolar soft part sarcoma; CLTC, clathrin heavy chain; NONO, non-POU domain-containing octamer-
binding; PRCC, papillary renal cell carcinoma; PSF, polypyrimidine tract binding protein-associated splicing factor; RCC, renal cell carcinomaDiagnostic Pathology 2009, 4:15 http://www.diagnosticpathology.org/content/4/1/15
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bodies, so, when present, psammomatous calcifications
are evidence in favor an Xp11.2 translocation RCC
[5,14,17]. IHC with conventional antibodies can be sug-
gestive; whereas clear cell RCC express epithelial markers
(cytokeratins and EMA) diffusely, Xp11.2 translocation
RCCs are frequently negative or only weakly positive
[5,14,17,19]. Although clear cells are uncommon in pap-
illary RCC, clear cells may be seen in the areas of degener-
ation associated with hemosiderin deposition.
Additionally, Xp11.2 translocation RCCs with prominent
eosinophilic cytoplasm might be confused with type 2
papillary RCCs [5,14,17].
The most distinctive IHC feature of Xp11.2 translocation
RCCs, absent in conventional clear cell and papillary
RCCs, is a detectable nuclear staining for the chimeric
(mutant) TFE3 protein [1-24], as in the case herein pre-
sented. The antibody used recognizes the C-terminal por-
tion of the TFE3 protein, which is retained in all TFE3
fusion proteins. Because native TFE3 is known to be
expressed constitutively and ubiquitously but not detecta-
ble in normal tissues by IHC, it is anticipated that all the
different Xp11.2/TFE3 gene fusions consistently lead to
the over-expression of TFE3 protein [5,7]. Previous studies
have reported specific immunohistochemical patterns
that are suggestive of the diagnosis of Xp11.2 transloca-
tion RCC, in the absence of TFE3 immunohistochemistry
[5,14,17,19]. Generally, the expression of cytokeratins
(AE1-AE3, Cam5.2, CK7, and EMA) and melanocytic
markers (HMB45 and melan A) were rare and weak, the
expression of vimentin was variable and weak, and that of
E-cadherin,  α-methylacyl-coenzyme A racemase, CD10
and RCC were common and strong in Xp11.2 transloca-
tion RCCs [5,14,17,19]. This typical immunoprofile of
previously reported Xp11.2 translocation RCCs is consist-
ent with that of the case herein presented, except for the
strong EMA positivity and weak RCC positivity in our
case. Generally, the absence of CK7 and EMA expression
(CK7-, EMA-), together with the overexpression of E-cad-
herin and CD10 (E-cadherin+, CD10+) in Xp11.2 translo-
cation RCCs have been suggested as useful tools in the
differential diagnosis of conventional clear cell RCCs
(CK7-, EMA+, E-cadherin-, CD10+) and papillary RCCs
(CK7+, E-cadherin+) [5,14,17,19]. Hence, the typical
immunoprofile of Xp11.2 translocation RCCs (CK7-,
EMA-, E-cadherin+, CD10+) may be helpful when TFE3
immunostaining is not available or doubtful
[5,14,17,19].
Xp11.2 translocation RCCs occur primarily, but not exclu-
sively, in children and young adults, and is believed to be
rather indolent even when diagnosed at advanced stages
[1-8]. However, there have been increasing recent reports
of Xp11.2 translocation RCC with aggressive clinical
course in patients aged 16 or older (Table 3) [9-24]. These
recent reports emphasize that, although the tumor mor-
phology in adult Xp11.2 translocation RCC was similar to
that in children, most of these adult patients had an
aggressive clinical course [9-24]. Although these recent
reports [9-24] indicate that Xp11.2 translocation RCCs
may be inherently more aggressive in adults than in chil-
dren; however, the relatively short follow-up periods cur-
rently available and the potential bias inherent on non-
consecutive case series and case reports preclude a defini-
tive prediction of behavior for individual patients. In con-
trast, the herein presented case of adult Xp11.2
translocation RCC occurring during the early second tri-
mester of pregnancy had a favorable clinical course with
the patient alive with no evidence of disease 27 months
after diagnosis and surgery. Therefore, there seems to be
clinicopathologic heterogeneity even in adults, but the
clinical and/or molecular basis for this heterogeneity
remains to be elucidated.
Renal tumors are rare in pregnancy and occur in approxi-
mately 1 per 1,000 pregnancies [28]. RCC is the most
common renal tumor reported in pregnancy, accounting
for about half of all primary renal tumors during preg-
nancy [28]. Over 80 cases of RCC occurring during preg-
nancy has been reported in the English Language medical
literature [28]. Most cases are incidentally diagnosed dur-
ing pregnancy (as in the case herein presented), and usu-
ally present as a large palpable mass, probably because of
more frequent abdominal and ultrasonographic examina-
tions during pregnancy [28]. The most common histo-
logic subtypes of RCC that have been reported during
pregnancy include conventional clear cell RCC, papillary
RCC and chromophobe RCC. To the best of our knowl-
edge, the case herein presented is the first report of Xp11.2
translocation RCC occurring during pregnancy. Bovio et
al. [23] recently reported the case of a 20-year-old preg-
nant female with placental, bone and retroperitoneal
lymph node metastases two years after radical nephrec-
tomy for Xp11.2 translocation RCC, but no evidence of
fetal metastasis. Hence, the initial diagnosis of Xp11.2
translocation RCC occurred prior to her pregnancy. Bovio
et al. [23] stated that given the need for systemic therapy
and risk of harm to the fetus, a Cesarean section was per-
formed at 33 weeks gestation. However, they did not spec-
ify whether subsequent systemic therapy was given, what
specific type of systemic therapy was given (if any), the
fate of the bone and retroperitoneal lymph node metas-
tases, and the final patient outcome (whether she was
alive with no evidence of disease, was alive with progres-
sive disease, or died of disease). Surgical resection (partial
or radical nephrectomy) is the preferred therapy in
patients with lower stage (potentially curable) tumors,
and may be performed in pregnant women. Nevertheless,
one of the major issues in the management of cancer in
pregnancy is timing of surgery.D
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Table 3: Treatment, Follow-Up, and Prognosis of Recently Reported Xp11.2 Translocation Renal Cell Carcinomas in Patients Aged 16 or Older
Treatment Pattern of Progression
Source, Year Pts, No. Age, y/Sex Primary 
Treatment
Additional Treatment Local 
Recurrence
Metastases Follow-Up Time, y Outcome
Dal Cin et al, 1998 [10] 1 53/F RN Resection of metastases None Lung, bone, liver, adrenal, 
retroperitoneal LNs
31 NS
Salles and Soto, 2005 [11] 1 58/F RN None None Renal hilar LNs 0.5 FOD
Mansouri et al, 2006 [12] 1 16/F RN Resection of metastases, ChemoRx, IFN-
α, IL-2
Yes Lung, bone, adrenal, lumbar-
aortic LNs
NS NS
Schinstine et al, 2006 [13] 1 57/F RN Resection of metastases None Lung 1 NS
Meyer et al, 2007 [14] 5 32.6 (mean)/5M 4 RN; 1 
renal Bx
Resection of metastases, ChemoRx, XRT, 
IL-2, investigational agents
Yes Lung, bone, liver, brain, 
mediastinal LNs
1.5 (mean) 2 DOD
Rais-Bahrami et al, 2007 [15] 1 23/M RN Resection of metastases, ChemoRx, 
investigational agents
None Lung, liver, retroperitoneal, 
supraclavicular, cervical and 
mediastinal LNs
17 DOD
Suzigan et al, 2007 [16] 1 17/F PN None None None 0.33 FOD
Argani et al, 2007 [17] 28 22–68 (range)/22F, 6M NS NS NS 5 hematogenous metastases NS 2 DOD
Armah and Parwani, 2008 [18] 1 33/M RN Resection of metastases, ChemoRx, XRT, 
IFN-α, IL-2
None Lung, liver, bone, brain, 
mediastinal LNs
0.58 DOD
Camparo et al, 2008 [19] 31 24.6 (mean)/18F, 13M 30 RN; 1 
renal Bx
Resection of metastases, ChemoRx, XRT, 
IFN-α, IL-2, investigational agents
NS Lung, liver, bone, LNs 0.5–7.67 (range) 5 DOD
Wu et al, 2008 [9] 3 17–20 (range)/1F, 2M 3RN Resection of metastases, investigational 
agents
Yes Retroperitoneal LNs 1.7–3.4 (range) 1 DOD
Gellar et al, 2008 [20] 4 16–17 (range)/3F, 1M 4RN ChemoRx, IFN-α, IL-2, investigational 
agents
None Lung, liver 1.17–15.42 (range) 1 DOD
Hintzy et al, 2008 [21] 6 28–42 (range)/4F, 2M NS NS NS 3 hematogenous metastases 2.67 (mean) 1 DOD
Komai et al, 2009 [22] 6 24–59 (range)/2F, 4M 6RN Resection of metastases, IFN-α, IL-2 None Lung, liver, LNs 0.75–11 (range) 2 DOD
Bovio et al, 2009 [23] 1 20/F RN NS None Placenta, bone, 
retroperitoneal LNs
2N S
Koie et al, 2009 [24] 1 28/M RN Resection of metastases, IFN-α, IL-2 Yes Lung, liver, adrenal, spleen, 
pancreas, psoas muscle, 
mesentery, descending colon, 
retroperitoneal LNs
2D O D
Bx, biopsy; ChemoRx, chemotherapy; DOD, died of disease; F, female; FOD, free of disease; IFN-α, interferon-α; IL-2, interleukin-2; LNs, lymph nodes; M, male; No., number; NS, not specified; PN, partial 
nephrectomy; Pts, patients; RN, radical nephrectomy; XRT, radiotherapy; y, yearsDiagnostic Pathology 2009, 4:15 http://www.diagnosticpathology.org/content/4/1/15
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The recommendation of surgery during the first and third
trimester of pregnancy is universally accepted, but the rec-
ommendation of surgery during the second trimester is
controversial [28]. It should be considered that delaying
surgery can potentially be harmful for the risk of metasta-
sis. However, when proposing surgery during the second
trimester of pregnancy, one should be aware of the poten-
tial risks of surgical manipulations, including uterine con-
tractions leading to fetal distress or even spontaneous
abortion. In the case herein presented, immediate surgery
was probably the best treatment option for RCC occurring
during early second trimester of pregnancy. Because pla-
cental and fetal metastases are rare, specific surveillance
guidelines and prognostic information are unclear for the
infant who does not present with metastases at birth, as in
the case herein presented.
While the increasing numbers of case reports of RCC aris-
ing during pregnancy could represent a chance occur-
rence, there is some evidence that there may be an
increased risk of the development of some neoplasms
(including RCC) during pregnancy, possibly related to
hormonal changes (including increased estrogen and beta
β-hCG levels) and increased immune tolerance [29].
Additionally, the increasing rates of RCC in women com-
pared to men over the past 30 years, the presence of ster-
oid hormone receptors in RCC tumor cells, the induction
of renal tumors in experimental animals with diethyl-
stilbestrol and estradiol, and the observation that obesity
is a consistent risk factor for RCC suggest a possible role of
reproductive or hormonal factors in RCC [29]. Kabat et al.
[29] recently demonstrated that high parity may be asso-
ciated with increased risk of RCC, and that oral contracep-
tive use may be associated with reduced risk. Indeed,
compared with nulliparous women, parous women were
at increased risk [hazard ratio (HR) = 1.78, 95% confi-
dence interval (CI) = 1.02–3.09] of RCC, and there was a
significant gradient of risk with increasing levels of parity:
relative to nulliparous women, women who had ≥ 5 preg-
nancies lasting 4 months or more had a 2.4-fold risk (HR
= 2.41, 95% CI = 1.27–4.59, P for trend 0.01) [29]. Ever
use of oral contraceptives was associated with a modest
reduction in risk. No associations were observed for age at
first live birth or use of hormone replacement therapy
[29].
Conclusion
The patient herein presented was older than typically
described for Xp11.2 translocation RCC. Although tumor
morphology showed some similar features to those in the
other recently reported cases of adult Xp11.2 transloca-
tion RCC with aggressive clinical courses [9-24], our
patient had a more favorable clinical course, a cystic mor-
phology, and a novel translocation involving chromo-
some 19. Hence, the consistent immunohistochemical
staining for TFE3 in all RCC with unusual gross and/or
histologic features, regardless of patient age, is likely to
expand the spectrum of Xp11.2 translocation RCC with
respect to age, clinical behavior, morphology, and molec-
ular abnormalities.
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